OPKO Health (OPK) Stock Price

OPKO Health Price

NASDAQ·CLOSED
1.32USD+0.0050 (+0.38 %)
Market closed

Revenue has compounded at 44.1% per year over the past 18 years to 606.88 M USD. OPKO Health's net margin stands at -37.2%, down from -1.7% several years earlier. Analysts set a median price target of 3.06 USD, implying 131.8% above the current price. Of 11 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 20% above its 52-week low.

OPKO Health stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of OPKO Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how OPKO Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing OPKO Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

OPKO Health Stock Price History
DateOPKO Health Price
8/6/20261.32 USD
8/5/20261.32 USD
8/4/20261.29 USD
8/3/20261.31 USD
7/31/20261.32 USD
7/30/20261.34 USD
7/29/20261.45 USD
7/27/20261.23 USD
7/23/20261.17 USD
7/22/20261.18 USD
7/21/20261.21 USD
7/20/20261.20 USD
7/17/20261.19 USD
7/16/20261.19 USD
7/15/20261.20 USD
7/14/20261.22 USD
7/13/20261.29 USD
7/10/20261.35 USD
7/9/20261.39 USD
7/8/20261.49 USD
7/7/20261.49 USD
7/6/20261.54 USD
7/2/20261.52 USD
7/1/20261.53 USD
6/30/20261.50 USD
6/29/20261.52 USD
6/26/20261.53 USD
6/25/20261.51 USD
6/24/20261.49 USD
6/23/20261.46 USD
6/22/20261.41 USD
6/18/20261.42 USD
6/17/20261.40 USD
6/16/20261.38 USD
6/15/20261.39 USD
6/12/20261.43 USD
6/11/20261.43 USD
6/10/20261.45 USD
6/9/20261.44 USD
6/8/20261.43 USD
6/5/20261.47 USD
6/4/20261.42 USD
6/3/20261.41 USD
6/2/20261.41 USD
6/1/20261.38 USD
5/29/20261.48 USD
5/28/20261.39 USD
5/27/20261.28 USD
5/26/20261.28 USD
5/22/20261.26 USD
5/21/20261.24 USD
5/20/20261.19 USD
5/19/20261.15 USD
5/18/20261.13 USD
5/15/20261.10 USD
5/14/20261.10 USD
5/13/20261.11 USD
5/12/20261.10 USD
5/11/20261.12 USD
5/8/20261.14 USD
5/7/20261.12 USD
5/6/20261.12 USD
5/5/20261.13 USD
5/4/20261.11 USD
5/1/20261.10 USD
4/30/20261.13 USD
4/29/20261.11 USD
4/28/20261.21 USD
4/27/20261.20 USD
4/24/20261.23 USD
4/23/20261.22 USD
4/22/20261.23 USD
4/21/20261.22 USD
4/20/20261.22 USD
4/17/20261.24 USD
4/16/20261.21 USD
4/15/20261.18 USD
4/14/20261.17 USD
4/13/20261.17 USD
4/10/20261.16 USD
4/9/20261.17 USD
4/8/20261.19 USD
4/7/20261.17 USD
4/6/20261.19 USD
4/2/20261.14 USD
4/1/20261.13 USD
3/31/20261.14 USD
3/30/20261.10 USD
3/27/20261.13 USD
3/26/20261.17 USD
3/25/20261.19 USD
3/24/20261.13 USD
3/23/20261.15 USD
3/20/20261.15 USD
3/19/20261.17 USD
3/18/20261.17 USD
3/17/20261.20 USD
3/16/20261.19 USD
3/13/20261.19 USD
3/12/20261.16 USD
3/11/20261.17 USD
3/10/20261.20 USD
3/9/20261.21 USD
3/6/20261.18 USD
3/5/20261.17 USD
3/4/20261.20 USD
3/3/20261.19 USD
3/2/20261.24 USD
2/27/20261.20 USD
2/26/20261.22 USD
2/25/20261.18 USD
2/24/20261.15 USD
2/23/20261.16 USD
2/20/20261.20 USD
2/19/20261.21 USD
2/18/20261.22 USD
2/17/20261.22 USD
2/13/20261.23 USD
2/12/20261.22 USD
2/11/20261.25 USD
2/10/20261.22 USD
2/9/20261.22 USD
2/6/20261.24 USD
2/5/20261.23 USD
2/4/20261.26 USD
2/3/20261.26 USD
2/2/20261.27 USD
1/30/20261.26 USD
1/29/20261.27 USD
1/28/20261.28 USD
1/27/20261.29 USD
1/26/20261.30 USD
1/23/20261.33 USD
1/22/20261.36 USD
1/21/20261.36 USD
1/20/20261.29 USD
1/16/20261.29 USD
1/15/20261.28 USD
1/14/20261.30 USD
1/13/20261.34 USD
1/12/20261.33 USD
1/9/20261.36 USD
1/8/20261.36 USD
1/7/20261.36 USD
1/6/20261.32 USD
1/5/20261.28 USD
1/2/20261.30 USD
12/31/20251.26 USD
12/30/20251.29 USD
12/29/20251.29 USD
12/26/20251.30 USD
12/24/20251.30 USD
12/23/20251.31 USD
12/22/20251.33 USD
12/19/20251.32 USD
12/18/20251.31 USD
12/17/20251.31 USD
12/16/20251.32 USD
12/15/20251.34 USD
12/12/20251.40 USD
12/11/20251.39 USD
12/10/20251.37 USD
12/9/20251.36 USD
12/8/20251.35 USD
12/5/20251.35 USD
12/4/20251.35 USD
12/3/20251.36 USD
12/2/20251.36 USD
12/1/20251.32 USD
11/28/20251.36 USD
11/26/20251.34 USD
11/25/20251.35 USD
11/24/20251.30 USD
11/21/20251.33 USD
11/20/20251.30 USD
11/19/20251.31 USD
11/18/20251.30 USD
11/17/20251.27 USD
11/14/20251.28 USD
11/13/20251.29 USD
11/12/20251.33 USD
11/11/20251.33 USD
11/10/20251.33 USD
11/7/20251.35 USD
11/6/20251.38 USD
11/5/20251.35 USD
11/4/20251.39 USD
11/3/20251.40 USD
10/31/20251.39 USD
10/30/20251.46 USD
10/29/20251.45 USD
10/28/20251.45 USD
10/27/20251.48 USD
10/24/20251.54 USD
10/23/20251.53 USD
10/22/20251.49 USD
10/21/20251.48 USD
10/20/20251.55 USD
10/17/20251.51 USD
10/16/20251.54 USD
10/15/20251.52 USD
10/14/20251.53 USD
10/13/20251.52 USD
10/10/20251.51 USD
10/9/20251.56 USD
10/8/20251.55 USD
10/7/20251.58 USD
10/6/20251.58 USD
10/3/20251.58 USD
10/2/20251.60 USD
10/1/20251.53 USD
9/30/20251.55 USD
9/29/20251.55 USD
9/28/20251.47 USD
9/25/20251.45 USD
9/24/20251.43 USD
9/23/20251.44 USD
9/22/20251.46 USD
9/19/20251.48 USD
9/18/20251.52 USD
9/17/20251.41 USD
9/16/20251.39 USD
9/15/20251.40 USD
9/12/20251.41 USD
9/11/20251.45 USD
9/10/20251.41 USD
9/9/20251.41 USD
9/8/20251.42 USD
9/5/20251.35 USD
9/4/20251.38 USD
9/3/20251.37 USD
9/2/20251.38 USD
8/29/20251.40 USD
8/28/20251.42 USD
8/27/20251.42 USD
8/26/20251.40 USD
8/25/20251.39 USD
8/22/20251.40 USD
8/21/20251.38 USD
8/20/20251.39 USD
8/19/20251.36 USD
8/18/20251.41 USD
8/15/20251.39 USD
8/14/20251.35 USD
8/13/20251.35 USD
8/12/20251.32 USD
8/11/20251.30 USD
Access this data via the Eulerpool API
Get Free API Key

OPKO Health Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
863.50 M USD
-175.29 M USD
-188.86 M USD
Jan 1, 2024
713.14 M USD
-152.07 M USD
-53.22 M USD
Jan 1, 2025
606.88 M USD
-147.74 M USD
-225.68 M USD
Jan 1, 2026 (e)
536.80 M USD
-79.44 M USD
-227.84 M USD
Jan 1, 2027 (e)
565.85 M USD
-83.74 M USD
-219.08 M USD
Jan 1, 2028 (e)
605.95 M USD
-89.68 M USD
-71.36 M USD
Jan 1, 2029 (e)
649.70 M USD
-96.15 M USD
-135.20 M USD
Jan 1, 2030 (e)
698.40 M USD
-103.36 M USD
-120.18 M USD

OPKO Health Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 9:09 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.491.220.970.990.901.441.771.000.860.710.610.540.570.610.650.70
439.56148.68-20.882.48-8.9959.2723.62-43.40-14.04-17.38-15.01-11.555.417.087.277.55
-19.9649.9635.7138.8936.5137.7032.7528.6936.8543.6221.1221.1221.1221.1221.1221.12
-98.00610.00345.00385.00329.00541.00581.00288.00318.00311.00128.00113.21119.34127.79137.08147.43
-98.00-89.00-276.00-166.00-283.0057.0018.00-379.00-175.00-152.00-147.00-79.00-83.00-89.00-96.00-103.00
-19.96-7.29-28.57-16.77-31.413.971.01-37.75-20.28-21.32-24.26-14.74-14.69-14.71-14.79-14.76
-30.00-48.00-305.00-153.00-314.0030.00-30.00-328.00-188.00-53.00-225.00-227.00-219.00-71.00-135.00-120.00
-82.4660.00535.42-49.84105.23-109.55-200.00993.33-42.68-71.81324.530.89-3.52-67.5890.14-11.11
545.07557.99562.90585.38622.47640.59651.78750.17751.51694.02765.52765.52765.52765.52765.52765.52
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales OPKO Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue OPKO Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare OPKO Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares OPKO Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against OPKO Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

OPKO Health stock margins

The OPKO Health margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OPKO Health. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OPKO Health.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
32.77 %
1.06 %
-1.70 %
Jan 1, 2022
28.70 %
-37.79 %
-32.70 %
Jan 1, 2023
36.84 %
-20.30 %
-21.87 %
Jan 1, 2024
43.61 %
-21.32 %
-7.46 %
Jan 1, 2025
21.10 %
-24.34 %
-37.19 %
Jan 1, 2026 (e)
21.10 %
-14.80 %
-42.44 %
Jan 1, 2027 (e)
21.10 %
-14.80 %
-38.72 %
Jan 1, 2028 (e)
21.10 %
-14.80 %
-11.78 %

OPKO Health Stock Revenue, EBIT, Earnings per Share

The OPKO Health earnings per share therefore indicates how much revenue OPKO Health has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
2.72 USD
0.03 USD
-0.05 USD
Jan 1, 2022
1.34 USD
-0.51 USD
-0.44 USD
Jan 1, 2023
1.15 USD
-0.23 USD
-0.25 USD
Jan 1, 2024
1.03 USD
-0.22 USD
-0.08 USD
Jan 1, 2025
0.79 USD
-0.19 USD
-0.29 USD
Jan 1, 2026 (e)
0.71 USD
-0.10 USD
-0.30 USD
Jan 1, 2027 (e)
0.75 USD
-0.11 USD
-0.29 USD
Jan 1, 2028 (e)
0.81 USD
-0.12 USD
-0.10 USD

OPKO Health business model & stock analysis

OPKO Health Inc is an American company specializing in diagnostics, biopharmaceuticals, and pharmaceutical products. It was founded in 1991 by Dr. Phillip Frost, who still serves as CEO. The company is headquartered in Miami, Florida, and employs around 6,000 people worldwide. In recent years, OPKO Health Inc has undergone strong expansion, particularly through several acquisitions of other companies. These include Bio-Reference Laboratories, Inc., a leading provider of diagnostic services, and EirGen Pharma, a European company specializing in the production of high-quality pharmaceuticals. The business model of OPKO Health Inc is based on the development and marketing of products and services in the field of diagnostics and medical research. The company operates numerous state-of-the-art laboratories worldwide, which conduct diagnostic tests, genetic analyses, and medical research. OPKO Health Inc offers a wide range of products and services distributed across multiple business areas. One important area is the diagnostics division, which offers a wide range of tests and services, including cancer diagnostics, blood tests, genetic analyses, and clinical trials. Another important business area of OPKO Health Inc is the biopharmaceutical division, which focuses on the development and marketing of innovative therapies and medical products. The company develops medications against cancer and other diseases, as well as vaccines and immunological therapies. A third important business area of OPKO Health Inc is the pharmaceutical products division, which specializes in the production and distribution of pharmaceutical products and generic medications. The company has a broad portfolio of products, ranging from over-the-counter painkillers to medications for rare diseases. One of OPKO Health Inc's key products is the 4Kscore test, a blood test for diagnosing prostate cancer. This test is approved in the US and Europe and has a high accuracy rate in detecting aggressive forms of cancer. Another important product of the company is Rayaldee-Tabs, an innovative vitamin D medication used for the treatment of patients with chronic kidney disease (CKD). The medication has shown high efficacy in clinical studies and is currently approved in the US and Europe. OPKO Health Inc has become a significant player in the field of medical research and diagnostics through strong expansion and numerous acquisitions in recent years. The company focuses on high quality and innovative technologies to best support its customers worldwide.

OPKO Health SWOT Analysis

Strengths

1. Diverse Product Portfolio: OPKO Health Inc offers a wide range of products in the pharmaceutical and diagnostics industry, providing a diversified revenue stream.

2. Strong Research and Development: OPKO Health consistently invests in research and development activities, allowing them to innovate and introduce new products or technologies to the market.

Weaknesses

1. Regulatory Challenges: The company operates in a highly regulated industry and faces challenges in complying with various government regulations and obtaining necessary approvals.

2. Financial Dependence: OPKO Health heavily relies on external funding and partnerships for its operations, which can impact its financial stability and flexibility.

Opportunities

1. Growing Demand for Genetic Testing: With increased awareness and interest in personalized medicine, there is a growing market opportunity for OPKO Health's genetic testing products.

2. Emerging Markets Expansion: Expanding into emerging markets with large populations and underdeveloped healthcare systems presents significant growth opportunities for the company.

Threats

1. Intense Competition: The healthcare and diagnostics industry is highly competitive, with numerous established players and new entrants, which may negatively impact OPKO Health's market share and profitability.

2. Regulatory and Legal Risks: Changes in regulations, lawsuits, or legal disputes can pose significant risks to the operations and reputation of OPKO Health.

OPKO Health Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

OPKO Health Employees
Details
Date
OPKO Health Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

OPKO Health Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

OPKO Health historical P/E ratio, EBIT multiple, and P/S ratio

OPKO Health annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

OPKO Health shares outstanding

The number of shares of OPKO Health was 765.52 M in 2025. This indicates how many shares OPKO Health is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
651.78 M Stocks
Jan 1, 2022
750.17 M Stocks
Jan 1, 2023
751.51 M Stocks
Jan 1, 2024
694.02 M Stocks
Jan 1, 2025
765.52 M Stocks
Jan 1, 2026 (e)
765.52 M Stocks
Jan 1, 2027 (e)
765.52 M Stocks
Jan 1, 2028 (e)
765.52 M Stocks

Current OPKO Health forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
72.73 % (8)
Hold
27.27 % (3)
Sell
0.00 % (0)
12M Price Target
3.06
Last Price
1.37
Currency
USD
12M Return Potential
123.36 %
LTM Return
0 %

OPKO Health Analyst Rating Actions

DateFirmActionRatingReliability
4/29/2026
Barrington Research
Barrington Research
DowngradeOutperformMarket Perform–
3/2/2026
Barrington Research
Barrington Research
MaintainedOutperform–
10/31/2025
Jefferies
Jefferies
DowngradeBuyHold47
10/30/2025
Barrington Research
Barrington Research
MaintainedOutperform–
5/1/2025
Barrington Research
Barrington Research
MaintainedOutperform–
4/7/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/19/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/12/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/12/2025
Barrington Research
Barrington Research
MaintainedOutperform–
3/3/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

OPKO Health Earnings Calls

2025

OPKO Health Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/30/2026-0.08USD-132.55 MUSD-2026 Q2
5/12/2026-0.07USD-131.82 MUSD-2026 Q1
2/26/2026-0.07USD-141.15 MUSD-2025 Q4
5/1/2024-0.07USD-195.10 MUSD-2024 Q1
2/21/2024-0.09USD-179.31 MUSD-2023 Q4
8/2/2023-0.10USD-191.47 MUSD-2023 Q2
5/8/2023-0.09USD-183.96 MUSD-2023 Q1
2/22/2023-0.11USD-173.98 MUSD-2022 Q4
11/8/2022-0.08USD-186.26 MUSD-2022 Q3
8/4/20220.01USD-331.78 MUSD-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the OPKO Health stock

29/100
4
Environment
55
Social
27
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

OPKO Health shareholder structure

% Name
6.36255%
Rubric Capital Management LP
Rubric Capital Management LP
6.36255%
RUBRIC CAPITAL MANAGEMENT LP
RUBRIC CAPITAL MANAGEMENT LP
4.82368%
BLACKROCK, INC.
BLACKROCK, INC.
4.30641%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
4.15708%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.96633%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
...

OPKO Health Beneficial Ownership Filings (SEC 13D/G)

Free Float
44.1%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
51.90%
Inc. Fed. Id. 75-2402409
Inc. Fed. Id. 75-2402409
SEC ↗
34.10%
FROST PHILLIP MD ET AL
FROST PHILLIP MD ET AL
SEC ↗
29.00%
Frost Gamma Investments Trust
Frost Gamma Investments Trust
SEC ↗
9.90%
75-2402409
75-2402409
SEC ↗
8.10%
OPKO HEALTH, INC.
OPKO HEALTH, INC.
SEC ↗
6.98%
David Rosen
David Rosen
SEC ↗
6.20%
NEW VALLEY LLC
NEW VALLEY LLC
SEC ↗
6.03%
Rubric Capital Management LP
Rubric Capital Management LP
SEC ↗
5.80%
Coe M. Magruder
Coe M. Magruder
SEC ↗
5.80%
Bruce C. Holbrook
Bruce C. Holbrook
SEC ↗

OPKO Health Executives and Management Board

15 members · avg. age 74 · 20 % women

PF

Dr. Phillip Frost (88)

Chairman of the Board, Chief Executive Officer · since 2007

2.16 M USD

Management

EZ

Dr. Elias Zerhouni (74)

President, Vice Chairman of the Board · since 2022

2.07 M USD
JH

Dr. Jane Hsiao (77)

Vice Chairman of the Board, Chief Technical Officer · since 2007

2.07 M USD
SR

Mr. Steven Rubin (64)

Executive Vice President - Administration, Director · since 2007

1.85 M USD
AL

Mr. Adam Logal (46)

Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer

1.81 M USD
CB

Dr. Charles Bishop (73)

Chief Executive Officer of OPKO Renal

–
TC

Dr. Tony Cruz (71)

Chief Executive Officer, Transition Therapeutics, Inc

–

Board of Directors

RP

Mr. Richard Pfenniger (69)

Independent Director

119,800.00 USD
RK

Dr. Richard Krasno (83)

Independent Director

84,900.00 USD
PL

Mr. Prem Lachman (64)

Independent Director

84,900.00 USD
JP

Mr. John Paganelli (90)

Independent Director · since 2003

77,400.00 USD
RM

Dr. Roger Medel (78)

Independent Director

62,400.00 USD
AY

Dr. Alice Yu (81)

Independent Director

54,900.00 USD

OPKO Health Supply Chain

OPKO Health Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
10 companies
#Nameβ 1YTrend
1
BioNano Genomics
Supplier·Life Sciences Tools & Services·US
0.66
0.43
0.88
0.80
0.41
0.32
—
#Nameβ 1YTrend
1
Sema4 Holdings A
Supplier·Customer·Health Care Providers & Services·US
0.30
-0.11
0.74
0.73
0.36
—
—
2
Pfizer
Supplier·Customer·Pharmaceuticals·US
0.14
-0.16
-0.09
0.45
-0.05
-0.42
-0.03
3
Vifor Pharma
Supplier·Customer·Pharmaceuticals·CH
-0.42
0.04
-0.62
-0.38
-0.41
-0.41
—
4
Eli Lilly
Supplier·Customer·Pharmaceuticals·US
0.49
0.46
0.07
-0.17
-0.22
-0.39
-0.20
5
Informa Plc
Supplier·Customer·Media·GB
0.40
0.23
0.57
-0.40
-0.42
-0.23
—

Frequently asked questions about OPKO Health

OPKO Health Inc's business model focuses on the discovery, development, and commercialization of innovative healthcare solutions. The company operates through two main segments: Pharmaceuticals and Diagnostics. In the Pharmaceuticals segment, OPKO develops and markets a range of specialty pharmaceutical products, with a particular focus on treating chronic diseases and conditions. The Diagnostics segment involves the development and distribution of a variety of diagnostic tests and technologies across multiple therapeutic areas. Through these segments, OPKO Health Inc aims to leverage its expertise and technologies to provide better healthcare solutions to patients around the world.

OPKO Health Inc primarily operates in the biotechnology and pharmaceutical industries.

Some of the main competitors of OPKO Health Inc in the market include companies such as AbbVie Inc, Thermo Fisher Scientific Inc, and Quest Diagnostics Incorporated.

OPKO Health Inc is a biopharmaceutical and diagnostics company that focuses on developing diagnostic tests and pharmaceutical products for various medical conditions. Founded in 1991, the company has grown to become a leading player in the healthcare industry. OPKO Health Inc has a diverse portfolio of products and services, including point-of-care diagnostics, molecular diagnostics, and pharmaceuticals for the treatment of conditions such as prostate cancer, metabolic disorders, and ophthalmic diseases. With its strong emphasis on research and development, OPKO Health Inc remains committed to improving patient outcomes and providing innovative solutions in the field of healthcare.

OPKO Health Inc has achieved several significant milestones. Some of these include the FDA approval of its RECORLEV™ (levoketoconazole) drug for the treatment of endogenous Cushing's syndrome, a rare hormonal disorder. The company also received FDA approval for its RAYALDEE® (calcifediol) extended-release capsules for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease. Furthermore, OPKO Health Inc has made advancements in its diagnostics segment through the development of proprietary molecular diagnostic tests for various diseases. These achievements showcase OPKO Health Inc's commitment to innovation and improving healthcare outcomes.

OPKO Health Inc is primarily present in several countries and regions. These include the United States, where the company is headquartered in Miami, Florida. Additionally, OPKO Health Inc has a significant presence in Chile, where it operates a subsidiary known as OPKO Chile. The company also has operations and partnerships in Israel, Mexico, and Ireland. With its global presence, OPKO Health Inc continues to expand its reach and make advancements in the healthcare industry across various markets.

OPKO Health Inc represents a commitment to advancing patient care and creating innovative solutions in healthcare. With a focus on precision medicine, the company strives to improve diagnostic testing and develop therapeutic treatments across various disease areas. OPKO Health Inc values scientific excellence, collaboration, and continuous innovation to enhance patient outcomes. By leveraging cutting-edge technologies and expertise, the company aims to address unmet medical needs and make a positive impact on global healthcare. Through its dedication to research and development, OPKO Health Inc is dedicated to improving the quality of life for individuals worldwide.

Analysts currently set an average price target of 3.63 USD for the OPKO Health stock (median: 3.06 USD), implying +164.9 % versus the latest price. The consensus is based on 11 analyst ratings.

OPKO Health Analyst Price Targets 2026

11 analysts currently rate the OPKO Health stock: 8 recommend buying, 3 holding and 0 selling. For 2026, analysts expect OPKO Health to generate revenue of 536.80 M USD and earnings per share of -0.30 USD.

OPKO Health Analyst Price Targets 2026

Converted at the current exchange rate, the OPKO Health share trades at 1.14 EUR (1.32 USD).

The OPKO Health share (OPK) is listed on 8 stock exchanges, including: NASDAQ (OPK), Frankfurt (XCY.F), München (XCY.MU), Düsseldorf (XCY.DU), London (0KCS.L), London (0KCS.L), SIX (Zürich) (XCY.SW).

OPKO Health Inc is a diversified healthcare company focused on a wide range of diagnostic, pharmaceutical, and biotechnology products and services. The company was founded in 1991 and is headquartered in Miami, Florida. The business model of OPKO is to offer innovative diagnostic and therapeutic solutions for a variety of diseases. The company operates various business segments, including diagnostics and pharmaceuticals, biotechnology, and research and development. Diagnostics and Pharmaceuticals: OPKO is a leading provider of medical diagnostic tests, including PSA tests for prostate cancer, 4KScore for aggressive prostate cancer, and Claros 1 for rapid diagnosis of heart disease. The company also offers a wide range of pharmaceutical products for the treatment of diseases such as hemophilia, growth hormone deficiency, and low testosterone. Biotechnology: OPKO owns and operates a variety of biotechnology companies and related product lines. DemosRx produces and distributes drugs for ophthalmology and dermatology, while Bio-Reference Laboratories provides medical testing and services for physicians and clinics, supporting their patients through a wide range of pathology tests. The combination of these two diagnostic units is intended to provide hospitals with a more comprehensive second opinion in diagnosis, particularly for patients who benefit from second opinions, recognized expert opinions, or patients removed from Soliris. Research and Development: OPKO invests significant sums in research and development of new medical technologies and drugs. The company has research projects in the areas of oncology, ophthalmology, obstetrics and gynecology, neurology, and gastroenterology. Some of OPKO's key projects include the development of drugs for the treatment of Alzheimer's, autism, osteoporosis, and diabetes. OPKO Health Inc aims to offer innovative solutions to patients and medical professionals worldwide. The company builds on its position as a leading provider of diagnostic products and services and is committed to translating innovative research findings into new drugs and therapies. Overall, OPKO Health Inc is a leading provider of medical diagnostic tests, pharmaceutical products, and biotechnology solutions with the goal of improving the lives of patients worldwide.

The expected revenue of OPKO Health is 536.80 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of OPKO Health is -227.84 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of OPKO Health is currently -4.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the OPKO Health stock.

The price-to-sales ratio (P/S) of OPKO Health is currently 1.88. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the OPKO Health stock.

The Eulerpool Quality Score for OPKO Health is 1/10.

The ISIN of OPKO Health is US68375N1037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of OPKO Health is A0MUUJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of OPKO Health is OPK. The ticker symbol is used to trade OPKO Health shares on the stock exchange.

OPKO Health paid dividends every year for the past 0 years.

OPKO Health is assigned to the 'Health' sector.

The dividends of OPKO Health are distributed in USD.

All fundamentals and in-depth analysis of OPKO Health

Our stock analysis for OPKO Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OPKO Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

OPKO Health Stock
OPKO Health Revenue→
OPKO Health Stock
OPKO Health Net Income→
OPKO Health Stock
OPKO Health P/E→
OPKO Health Stock
OPKO Health P/S→
OPKO Health Stock
OPKO Health EBIT→
OPKO Health Stock
OPKO Health Dividend→
OPKO Health Stock
OPKO Health Directors Dealings→
OPKO Health Stock
OPKO Health Stocks→
OPKO Health Stock
OPKO Health Market capitalization→
OPKO Health Stock
OPKO Health Debt→
OPKO Health Stock
OPKO Health Liabilities→
OPKO Health Stock
OPKO Health Equity→
OPKO Health Stock
OPKO Health AAQS→
OPKO Health Stock
OPKO Health Employees→
OPKO Health Stock
OPKO Health ROE→
OPKO Health Stock
OPKO Health ROA→
OPKO Health Stock
OPKO Health ROCE→
OPKO Health Stock
OPKO Health News→
OPKO Health Stock
OPKO Health Analyst Price Targets→

Health Stocks

OptiBiotix HealthOPC Pharmaceutical JSCOptimizeRxOnyx HealthcareOption Care HealthONWARD MedicalOptiPharm CoOno Pharmaceutical CoOptiscan ImagingOnkure TherapeuticsOptomed OyjOnesource Specialty PharmaAll Stocks A–Z →